Last updated: September 11, 2026
Human fibrinogen concentrate is a specialized plasma-derived biologic used for congenital fibrinogen deficiencies and, in some markets, acquired hypofibrinogenemia associated with major bleeding. The market is concentrated among CSL Behring, Octapharma, and a small number of regional plasma-product suppliers. Growth is driven by diagnosis, hospital adoption, blood-management programs, and supply reliability rather than broad patient volume.
RiaSTAP and Fibryga are the principal U.S. commercial products. RiaSTAP has the earlier U.S. approval and established clinical use. Fibryga entered the U.S. market in 2017 and increased competitive pressure. Neither manufacturer publicly reports a standalone global revenue figure for its fibrinogen concentrate franchise, limiting precise product-level financial modeling.
What is human fibrinogen concentrate used for?
Human fibrinogen concentrate replaces fibrinogen, a plasma protein required for clot formation. It is administered intravenously and is manufactured from pooled human plasma through fractionation and purification.
The main clinical segments are:
| Segment |
Clinical use |
Commercial relevance |
| Congenital fibrinogen deficiency |
Afibrinogenemia, hypofibrinogenemia, and some dysfibrinogenemia cases |
Core labeled market for U.S. products |
| Acquired hypofibrinogenemia |
Major bleeding, cardiac surgery, trauma, obstetrics, and liver transplantation |
Larger potential market but more dependent on local guidelines and reimbursement |
| Perioperative hemostasis |
Replacement during procedures with severe fibrinogen depletion |
Drives hospital protocol adoption |
| Pediatric and neonatal care |
Congenital deficiency and severe bleeding |
High clinical need, low absolute volume |
RiaSTAP is FDA-approved for the on-demand treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Fibryga is FDA-approved for on-demand treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency and for perioperative management of bleeding in adults and children with acquired fibrinogen deficiency, including congenital cardiac surgery, postpartum hemorrhage, and other settings described in its labeling.[1][2]
How large is the fibrinogen concentrate market?
The global market is generally estimated by commercial market researchers in the high hundreds of millions to low billions of dollars annually, depending on whether the analysis includes only licensed fibrinogen concentrates or also cryoprecipitate, fibrin sealants, and broader coagulation products.
A reliable product-level market size is difficult to establish because:
- CSL does not disclose RiaSTAP revenue separately.
- Octapharma does not disclose Fibryga revenue separately.
- Some countries use cryoprecipitate or fresh frozen plasma as lower-cost alternatives.
- Acquired bleeding use varies by hospital protocol and is not uniformly approved.
- Market reports use different definitions of "fibrinogen concentrate."
The most defensible commercial view is that congenital deficiency is a small, high-value orphan market, while acquired bleeding is the main expansion opportunity. Revenue growth therefore depends more on conversion from plasma components and increased testing than on population growth.
Which companies manufacture human fibrinogen concentrate?
CSL Behring
CSL Behring markets RiaSTAP in the United States. Its parent, CSL Limited, reports performance by major business segment rather than by individual product. The company has a large plasma-collection and fractionation infrastructure, which supports supply security and manufacturing scale.
RiaSTAP benefits from:
- Early U.S. market entry.
- Established use in congenital fibrinogen deficiency.
- CSL Behring’s specialty hospital sales organization.
- Existing relationships with hematology, surgery, trauma, and transfusion services.
Its main commercial limitation is the relatively narrow U.S. labeled indication compared with broader clinical use of fibrinogen replacement in acquired bleeding.
Octapharma
Octapharma markets Fibryga. The product has a broader U.S. label than RiaSTAP because it includes perioperative management of acquired fibrinogen deficiency. Fibryga also has European and international commercial presence.
Octapharma’s competitive position is supported by:
- Broader label positioning in the United States.
- Global plasma-product distribution.
- Use in congenital and acquired deficiency settings.
- Integration with hospital coagulation and blood-management programs.
Regional and international suppliers
Other fibrinogen products are marketed in selected jurisdictions, including Haemocomplettan P and equivalent products associated with CSL Behring’s international portfolio. Product availability differs by country because plasma-derived medicines are regulated through national or regional marketing authorizations, tender systems, and hospital procurement channels.
How does RiaSTAP compare with Fibryga?
| Attribute |
RiaSTAP |
Fibryga |
| Manufacturer |
CSL Behring |
Octapharma |
| Active ingredient |
Human fibrinogen |
Human fibrinogen |
| U.S. approval |
2009 |
2017 |
| Core U.S. indication |
Congenital fibrinogen deficiency |
Congenital and acquired fibrinogen deficiency in labeled settings |
| Dosage form |
Intravenous lyophilized powder |
Intravenous lyophilized powder |
| U.S. orphan status |
Associated with rare-disease use |
Associated with rare-disease use |
| Commercial position |
Incumbent, established specialty product |
Competitive entrant with broader label |
| Key differentiation |
Longevity, CSL infrastructure, physician familiarity |
Label breadth and clinical positioning |
The products are clinically substitutable in some settings, but procurement decisions can depend on dosing instructions, reconstitution time, inventory availability, contract pricing, local guidelines, and physician experience.
What is the FDA regulatory status of fibrinogen concentrate?
RiaSTAP and Fibryga are FDA-approved biologic products regulated under biologics licensing applications. They are not conventional small-molecule drugs approved through abbreviated new drug applications.
The regulatory profile has several commercial consequences:
- Generic substitution does not operate in the same manner as for ordinary tablets or injectable small molecules.
- A competing manufacturer generally requires its own biologics license or an approved biosimilar pathway.
- Plasma source, viral clearance, manufacturing consistency, and clinical comparability are major regulatory issues.
- Hospital purchasing is influenced by supply continuity and manufacturing history, not only list price.
The products are plasma-derived rather than recombinant. Their manufacturing depends on donor plasma collection, fractionation capacity, pathogen-reduction controls, and release testing.
What is the Orange Book and Purple Book status?
Human fibrinogen concentrate products are biologics. The FDA Orange Book is principally used for approved small-molecule drug products and does not provide the same patent-certification framework for RiaSTAP or Fibryga that applies to an ordinary tablet or injectable drug.
The FDA Purple Book is the relevant reference for licensed biological products and biosimilar or interchangeable-biologic determinations. RiaSTAP and Fibryga are not interchangeable products merely because they contain human fibrinogen. A follow-on manufacturer would need to establish the applicable biological comparability or biosimilarity standard and obtain FDA approval under the appropriate pathway.[3]
Because these products are plasma-derived, manufacturing comparability can be more difficult than for a simple recombinant protein. The practical barrier is likely to be a combination of clinical evidence, plasma sourcing, process validation, regulatory review, and commercial scale.
When does fibrinogen concentrate lose exclusivity?
There is no single small-molecule-style patent expiration date that determines market entry for RiaSTAP or Fibryga.
The principal exclusivity layers are:
| Exclusivity layer |
Relevance |
| Orphan-drug exclusivity |
Can restrict approval of the same drug for the same indication for seven years in the United States, subject to statutory exceptions |
| Biologics exclusivity |
Reference biological products may receive 12 years of reference-product exclusivity under the Public Health Service Act |
| Patents |
May cover formulation, purification, viral inactivation, administration, or manufacturing processes |
| Trade secrets |
Plasma fractionation, purification, quality controls, and process parameters may remain difficult to replicate |
| Regulatory approvals |
Country-specific approvals and procurement status affect actual market access |
RiaSTAP’s 2009 approval means its earliest U.S. biologics exclusivity period would have expired long ago. That does not eliminate patent, manufacturing, regulatory, or commercial barriers. Fibryga’s 2017 U.S. approval similarly places its statutory biologics-exclusivity period in the past or near the end of the relevant period, depending on the legally established reference-product date. Actual entry risk remains product-specific.
What patents protect fibrinogen concentrate?
Protection is likely to center on manufacturing and formulation rather than a new chemical entity. Relevant patent categories include:
- Purification and fractionation of fibrinogen from human plasma.
- Stabilization of fibrinogen during drying and storage.
- Viral inactivation and pathogen-clearance processes.
- Reconstitution characteristics.
- High-purity formulations.
- Methods for treating congenital or acquired fibrinogen deficiency.
- Container, excipient, and lyophilization systems.
Patent protection for plasma-derived products is often less decisive than for a novel small molecule because a competitor may design around a process claim while relying on its own plasma and fractionation platform. The more durable barriers are manufacturing know-how, regulatory validation, donor-plasma access, and hospital supply contracts.
Publicly available product labeling and regulatory databases do not establish a single, universally controlling patent expiration date for the commercial fibrinogen products. Any freedom-to-operate review would need a live patent-family analysis in the relevant jurisdictions, including continuation, divisional, reissue, and terminal-disclaimer status.
Are there Paragraph IV challenges to RiaSTAP or Fibryga?
Paragraph IV litigation is associated primarily with abbreviated new drug applications for small-molecule products. It is not the normal pathway for a plasma-derived biologic such as RiaSTAP or Fibryga.
A competing biologic would more likely proceed through:
- A standalone biologics license application.
- A biosimilar application under section 351(k) of the Public Health Service Act.
- A patent-dispute process under the Biologics Price Competition and Innovation Act.
- A litigation strategy involving process, formulation, manufacturing, or method-of-use patents.
No major public Paragraph IV generic challenge is the central market-access issue for these products. The more material competitive question is whether a new plasma-derived or biosimilar-like product can obtain approval and achieve reliable commercial supply.
What drives the financial trajectory of fibrinogen concentrate?
The financial trajectory is shaped by five variables.
Diagnosis and testing
Congenital fibrinogen disorders are rare and underdiagnosed. Wider use of fibrinogen activity testing, genetic diagnosis, and specialized coagulation services can expand the treated population.
Conversion from cryoprecipitate
In acquired bleeding, fibrinogen concentrate competes with cryoprecipitate. Concentrate has advantages in standardized dosing, rapid preparation, lower logistical burden, and reduced exposure to multiple donors. Cryoprecipitate can remain cheaper and more familiar in hospitals with established transfusion infrastructure.
Blood-management protocols
Adoption increases when hospitals use point-of-care viscoelastic testing, such as thromboelastography or rotational thromboelastometry, to identify low fibrinogen levels and guide replacement. Protocol-driven use can increase consistency but may also limit empiric dosing.
Plasma supply and manufacturing cost
Fibrinogen concentrate is dependent on human plasma. Plasma collection costs, donor supply, regulatory requirements, energy, labor, and batch release testing affect gross margins. Large integrated manufacturers have an advantage because they control or access upstream plasma capacity.
Reimbursement and tenders
The product is usually purchased by hospitals, government systems, or specialist distributors. Revenue is sensitive to tender awards, formulary decisions, negotiated discounts, and country-specific reimbursement. A broader label does not automatically produce higher revenue if hospitals continue using cryoprecipitate.
What is the revenue exposure for CSL Behring and Octapharma?
Neither CSL nor Octapharma publicly reports a standalone revenue line for RiaSTAP or Fibryga. Product-level revenue estimates published by commercial market researchers should therefore be treated as modeled figures rather than audited disclosures.
The products are strategically important but are unlikely to be major revenue drivers relative to broader plasma-derived immunoglobulin, albumin, and specialty hematology portfolios. Their value is concentrated in:
- High unit economics relative to routine blood components.
- Specialty-market positioning.
- Hospital account access.
- Cross-selling with other coagulation products.
- Long-term contracts and supply reliability.
The financial profile is likely characterized by high gross margins but modest absolute volume. Growth can be strong from a small base when acquired-bleeding use expands.
What generic or biosimilar entry risks exist?
Near-term entry risk is moderate rather than high.
The main barriers are:
- Limited patient volume for congenital disease.
- High cost of plasma collection and fractionation.
- Need for validated pathogen-clearance processes.
- Clinical and regulatory requirements for a biologic product.
- Hospital preference for proven supply reliability.
- Difficulty obtaining sufficient plasma and manufacturing scale.
- Patent and trade-secret protections around processing.
The largest risk may come from product substitution rather than a traditional generic launch. Hospitals can substitute cryoprecipitate, use alternative fibrinogen products, or adopt a competing supplier through a tender without waiting for a direct biosimilar.
What patent litigation and settlement activity affects the market?
There is no widely reported, market-defining patent litigation campaign comparable with litigation in major small-molecule or blockbuster biologic markets. The principal legal risks are more likely to arise from:
- Patent disputes over purification or stabilization processes.
- Trade-secret claims involving plasma fractionation.
- Regulatory challenges to competing biologics.
- Supply-contract disputes.
- Product liability and manufacturing-quality matters.
The absence of prominent public litigation does not mean the estates are irrelevant. For plasma-derived products, process patents and manufacturing know-how can be commercially important even when litigation is limited.
How does fibrinogen concentrate compare with cryoprecipitate?
| Factor |
Fibrinogen concentrate |
Cryoprecipitate |
| Composition |
Standardized fibrinogen product |
Variable pooled blood component |
| Preparation |
Rapid reconstitution |
Thawing and preparation required |
| Dose consistency |
Higher |
More variable |
| Donor exposure |
Controlled pooled-plasma product |
Multiple donor units, depending on use |
| Storage |
Pharmaceutical inventory model |
Blood-bank inventory model |
| Cost |
Usually higher per treatment |
Often lower direct acquisition cost |
| Supply risk |
Depends on plasma manufacturing |
Depends on blood donation and local inventory |
| Regulatory status |
Licensed biologic |
Blood component regulated under blood-product rules |
| Growth driver |
Protocol adoption and convenience |
Established practice and cost advantage |
The market will expand fastest where hospitals value standardized dosing, rapid administration, and reduced blood-bank workload enough to justify the price premium.
What is the outlook for fibrinogen concentrate from 2025 onward?
The base-case outlook is moderate growth with uneven geographic performance.
| Period |
Expected market dynamic |
| 2025-2027 |
Continued competition between RiaSTAP and Fibryga; increased protocol-based use in acquired bleeding |
| 2027-2030 |
Gradual expansion through blood-management programs, trauma centers, obstetric hemorrhage protocols, and cardiac surgery |
| Beyond 2030 |
Greater pressure from hospital tenders, regional competitors, and potential follow-on biologics |
The strongest growth opportunities are in the United States, Western Europe, Japan, Australia, and high-resource hospital systems. Emerging-market growth will depend on reimbursement, local plasma-product manufacturing, and public procurement.
The principal downside risks are lower-than-expected clinical adoption, persistent cryoprecipitate preference, plasma shortages, manufacturing interruptions, and price concessions in tenders.
Key takeaways
- RiaSTAP and Fibryga are the leading U.S. human fibrinogen concentrate products.
- Congenital fibrinogen deficiency is the established orphan market; acquired bleeding is the main expansion segment.
- Fibryga has a broader U.S. label for acquired fibrinogen deficiency than RiaSTAP.
- Product-level revenue is not publicly disclosed by CSL Behring or Octapharma.
- The market is protected less by a single dominant patent than by plasma supply, manufacturing know-how, regulatory validation, and hospital contracts.
- Paragraph IV litigation is not the main competitive risk because these are plasma-derived biologics.
- Cryoprecipitate remains the principal alternative and limits pricing power.
- Moderate long-term growth is likely, with the highest upside from protocol-driven use in surgery, trauma, and obstetric hemorrhage.
FAQs
Is fibrinogen concentrate a blood product or a biologic drug?
It is a plasma-derived biologic manufactured from pooled human plasma and regulated as a licensed biological product.
Can fibrinogen concentrate replace cryoprecipitate?
It can replace cryoprecipitate in selected clinical settings, subject to product labeling, institutional protocols, physician judgment, and reimbursement.
Which fibrinogen concentrate has the broader U.S. label?
Fibryga has a broader U.S. label because it includes certain perioperative uses in acquired fibrinogen deficiency in addition to congenital deficiency.
Is there a recombinant human fibrinogen product competing with RiaSTAP?
The principal marketed products discussed here are plasma-derived. Recombinant fibrinogen development has not displaced the established plasma-derived products in routine commercial use.
What is the biggest investment risk in the fibrinogen concentrate market?
The largest risk is slower conversion from cryoprecipitate than expected. Plasma supply constraints, hospital price pressure, and limited product-level revenue disclosure are also material risks.
References
- U.S. Food and Drug Administration. (2024). RiaSTAP fibrinogen concentrate, human: Prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Fibryga fibrinogen concentrate, human: Prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
- CSL Limited. (2024). Annual report 2024. CSL Limited.
- Octapharma AG. (2024). Fibryga product information and clinical resources. Octapharma.
- U.S. Food and Drug Administration. (2023). Biologics Price Competition and Innovation Act of 2009: Biosimilar biological products. FDA.
